ATEZOLIZUMAB, COBIMETINIB, VEMURAFENIB
NEO-TIM
Phase 2 small_molecule active
Quick answer
ATEZOLIZUMAB, COBIMETINIB, VEMURAFENIB for high-risk, surgically resectable BRAF mutated and wild-type Melanoma is a Phase 2 program (small_molecule) at Fondazione Telethon ETS with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Fondazione Telethon ETS
- Indication
- high-risk, surgically resectable BRAF mutated and wild-type Melanoma
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active